SavaDx
Alzheimer's Disease Detection
ResearchPre-clinical Development
Key Facts
Indication
Alzheimer's Disease Detection
Phase
Research
Status
Pre-clinical Development
Company
About Cassava Sciences
Cassava Sciences is a mission-driven biotech focused on developing transformative treatments for Alzheimer's disease, a market with profound unmet need. Its core strategy is built on a unique scientific platform targeting altered filamin A (FLNA) protein to stabilize disease pathology. The company's primary achievement is the advancement of its lead drug, simufilam, into two large, global Phase 3 efficacy and safety trials. Cassava's strategy hinges on successfully demonstrating simufilam's clinical benefit to secure regulatory approval and address a multi-billion dollar market.
View full company profileTherapeutic Areas
Other Alzheimer's Disease Detection Drugs
| Drug | Company | Phase |
|---|---|---|
| SOBA-AD | AltPep | Preclinical |
| pTau217 Antibody | ALZpath | IVD |
| LucentAD Complete | Quanterix | FDA 510(k) Submission |